van Hal Sebastiaan J, Herring Belinda, Deris Zaquan, Wang Bin, Saksena Nitin K, Dwyer Dominic E
Centre for Infectious Diseases and Microbiology, ICPMR Westmead Hospital, University of Sydney, Westmead 2145, NSW, Australia.
Retrovirology. 2009 Feb 9;6:12. doi: 10.1186/1742-4690-6-12.
In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not identified, although the accessory mutation G140S was detected. A link with previous antiretroviral therapy, intra-subtype B divergence across the integrase gene and transmission of integrase polymorphisms were also noted. Based on these findings, we would recommend ongoing surveillance of integrase mutations, and integrase region sequencing for patients prior to commencement of integrase inhibitors.
在最近一份整合酶序列总结中，主要整合酶抑制剂突变很少见。在一项对未接受过整合酶抑制剂治疗的澳大利亚HIV-1序列的综述中，未发现主要突变，尽管检测到了辅助突变G140S。还注意到与先前抗逆转录病毒治疗的关联、整合酶基因内B亚型间的差异以及整合酶多态性的传播。基于这些发现，我们建议对整合酶突变进行持续监测，并在开始使用整合酶抑制剂之前对患者进行整合酶区域测序。
